Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

• Published in: BMC cancer 2020-04, Vol.20 (1), p.359-359, Article 359
• Main Authors: Bloom, Meghan J, Jarrett, Angela M, Triplett, Todd A, Syed, Anum K, Davis, Tessa, Yankeelov, Thomas E, Sorace, Anna G
• Format: Article
• Language: English
• Subjects: Analysis; Angiogenesis; Animal models; Animals; Antibodies; Antineoplastic Agents, Immunological - pharmacology; Apoptosis; Automation; Bevacizumab; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - immunology; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; BT474; Cancer therapies; CCL21 protein; Cell cycle; Cell Proliferation; Chemotherapy; CXCL10 protein; Cytokines; Cytotoxicity; Dendritic cells; Disease Models, Animal; Epidermal growth factor; Epidermal growth factors; ErbB-2 protein; Female; Flow cytometry; Herceptin; Humans; Hypoxia; IL-1β; Immunohistochemistry; Immunomodulation; Immunosuppressive agents; Immunotherapy; Infiltration; Inflammation; Laboratories; Macrophages; Macrophages - drug effects; Macrophages - immunology; Macrophages - metabolism; Maturation; Metastases; Mice; Mice, Nude; Microvessels - drug effects; Microvessels - immunology; Microvessels - metabolism; Monoclonal antibodies; Myeloid Cells - drug effects; Myeloid Cells - immunology; Myeloid Cells - metabolism; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - immunology; Receptor, ErbB-2 - metabolism; Software industry; Spleen; Targeted cancer therapy; Trastuzumab; Trastuzumab - pharmacology; Tumor associated macrophages; Tumor Cells, Cultured; Tumor Microenvironment; Tumor necrosis factor-α; Tumors; Vascular endothelial growth factor; Xenograft Model Antitumor Assays
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-06868-4

Therapy targeted to the human epidermal growth factor receptor type 2 (HER2) is used in combination with cytotoxic therapy in treatment of HER2+ breast cancer. Trastuzumab, a monoclonal antibody that targets HER2, has been shown pre-clinically to induce vascular changes that can increase delivery of chemotherapy. To quantify the role of immune modulation in treatment-induced vascular changes, this study identifies temporal changes in myeloid cell infiltration with corresponding vascular alterations in a preclinical model of HER2+ breast cancer following trastuzumab treatment. HER2+ tumor-bearing mice (N = 46) were treated with trastuzumab or saline. After extraction, half of each tumor was analyzed by immunophenotyping using flow cytometry. The other half was quantified by immunohistochemistry to characterize macrophage infiltration (F4/80), vascularity (CD31 and α-SMA), proliferation (Ki67) and cellularity (H&E). Additional mice (N = 10) were used to quantify differences in tumor cytokines between control and treated groups. Immunophenotyping showed an increase in macrophage infiltration 24 h after trastuzumab treatment (P ≤ 0.05). With continued trastuzumab treatment, the M1 macrophage population increased (P = 0.02). Increases in vessel maturation index (i.e., the ratio of α-SMA to CD31) positively correlated with increases in tumor infiltrating M1 macrophages (R = 0.33, P = 0.04). Decreases in VEGF-A and increases in inflammatory cytokines (TNF-α, IL-1β, CCL21, CCL7, and CXCL10) were observed with continued trastuzumab treatment (P ≤ 0.05). Preliminary results from this study in a murine model of HER2+ breast cancer show correlations between immune modulation and vascular changes, and reveals the potential for anti-HER2 therapy to reprogram immunosuppressive components of the tumor microenvironment. The quantification of immune modulation in HER2+ breast cancer, as well as the mechanistic insight of vascular alterations after anti-HER2 treatment, represent novel contributions and warrant further assessment for potential clinical translation.